華仁藥業(300110.SZ)業績快報:2020年淨利升123.57%至9404.91萬元
格隆匯 2 月 26日丨華仁藥業(300110.SZ)披露2020年度業績快報,報吿期內,公司實現營業收入16.16億元,同比增長10.56%;營業利潤1.13億元,同比上升52.44%;利潤總額1.11億元,同比上升64.66%;歸屬上市公司股東的淨利潤9404.91萬元,同比增長123.57%;基本每股收益0.080元。
報吿期內,由於疫情原因,醫院患者量、手術量均大幅下降,公司大輸液業務受到一定影響。公司積極應對困難,一方面全力做好疫情防控、復工復產工作,確保產品穩定、及時供應,做好存量客户的維護與管理,另一方面,抓住市場機會,加大新客户開發力度,進一步拓展增量市場,通過全員的共同努力,各項業務逐步恢復。
面對突如其來的疫情,口罩、防護服等防護用品迅速出現嚴重短缺的局面,為了踐行國有上市公司的社會責任,滿足市場需求,公司在危機中開新局,積極佈局口罩、防護服、熔噴布等防護產品,以實際行動支持疫情防控工作,醫療防護用品為公司貢獻了部分收入和利潤。公司積極參與疫情防控過程中,政府給予大力支持,本年度收到的政府補助較同期有所增加。
在對外投資方面,為了積極應對國家集採,抓住行業調整的市場機遇,充分發揮協同效應,實現規模效益,公司收購了廣西裕源藥業有限公司、浦北縣新科藥品包裝有限公司100%股權,並於2020年11月6日辦理完畢股權轉讓的工商登記手續。根據《企業會計準則》的規定,自2020年11月起,廣西裕源藥業有限公司、浦北縣新科藥品包裝有限公司納入合併範圍。此外,公司進一步優化資金結構,財務費用較去年同期下降。
綜上所述,公司整體經營業績較去年同期大幅增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.